Company intelligence / Profile preview

AcroImmune

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Phase 1

Overview

AcroImmune developed a pipeline of best-in-class and first-in-class immunotherapies targeting solid tumors and inflammatory diseases, including bispecific antibodies like PD‑1/VEGF-targeting AI‑081, with several programs at or near the IND-filing or early clinical stages. The company was acquired by OncoC4 in September 2024 to expand the combined immunotherapy pipeline and manufacturing capabilities.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate (ADC)Other biologics
Industry: Biotech

Drug pipeline

1 asset

AI-081

Phase 1

Indications: Solid tumors

Partnerships

Close relationship with OncoC4 Inc.; no major external pharma partnerships disclosed publicly.

Beyond the preview

Go deeper on AcroImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcroImmune.

Explore the full profile